No Data
BAIYUNSHAN PH (00874.HK): Liu Luan has been nominated as a candidate for the Shareholder representative supervisor.
On December 24, Gelonghui reported that BAIYUNSHAN PH (00874.HK) announced that the Board of Directors received a notification from the company's Board of Supervisors, stating that the chairman of the Board of Supervisors, Cai Ruiyu, resigned from his position as the chairman of the ninth Board of Supervisors and as the shareholder representative supervisor due to work adjustments. On the same day, it was announced that Liu Min was nominated as a candidate for shareholder representative supervisor at the tenth meeting of the ninth Board of Supervisors to be held on December 24, 2024.
Express News | Guangzhou Baiyunshan Pharmaceutical - Proposes to Appoint Li Xiaojun as an Executive Director of 9TH Session
Baiyunshan Unit Gets Authorization for Indian Gooseberry Lozenge Production
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) May Have Issues Allocating Its Capital
Baiyunshan Pharmaceutical's Unit Gets Nod to Cefuroxime Sodium for Injection's Amendment
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
